Lantern Pharma Inc (LTRN)

Nov 20, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Nov 19, 2024

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace

Nov 19, 2024

Nov 19, 2024

Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com

Nov 19, 2024

Nov 14, 2024

32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.

Nov 14, 2024

Nov 12, 2024

LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India

Nov 11, 2024

Nov 09, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada

Nov 09, 2024

Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance

Nov 08, 2024

Nov 08, 2024

Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks

Nov 08, 2024

Nov 07, 2024

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace

Nov 07, 2024

Nov 05, 2024

Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan

Nov 05, 2024

Nov 05, 2024

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Simply Wall St

Nov 05, 2024

Oct 31, 2024

Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine

Oct 31, 2024

Oct 31, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace

Oct 31, 2024

Oct 29, 2024

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com

Oct 29, 2024

Oct 23, 2024

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire

Oct 23, 2024

Oct 21, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire

Oct 21, 2024

Oct 16, 2024

FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada

Oct 16, 2024

Oct 15, 2024

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace

Oct 15, 2024

Oct 15, 2024

FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive

Oct 15, 2024

Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Oct 09, 2024

Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com

Oct 09, 2024

Sep 30, 2024

After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph

Sep 30, 2024

Sep 26, 2024

11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex

Sep 26, 2024

Sep 23, 2024

Lantern Pharma secures three new FDA rare disease tags - Investing.com

Sep 23, 2024

Sep 23, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace

Sep 23, 2024

Sep 23, 2024

Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch

Sep 23, 2024

Sep 11, 2024

Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare

Sep 11, 2024

Aug 31, 2024

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance

Aug 31, 2024

Aug 28, 2024

NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma - OncLive

Aug 28, 2024

Aug 27, 2024

11 Penny Stocks That Will Make You A Millionaire - Insider Monkey

Aug 27, 2024

Aug 18, 2024

LTRN (Lantern Pharma) EPS (Basic) : $-1.65 (TTM As of Jun. 2024) - GuruFocus.com

Aug 18, 2024

Aug 18, 2024

The Targeted Pulse: Apalutamide Provides a Faster, Deeper PSA Response vs Enzalutamide, Vorasidenib Receives Approval in Glioma, and More - Targeted Oncology

Aug 18, 2024

Aug 18, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update - Defense World

Aug 18, 2024

Aug 17, 2024

LTRN (Lantern Pharma) 50-Day SMA : $4.42 (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024

Aug 16, 2024

LTRN (Lantern Pharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024

Aug 14, 2024

Q3 2024 Earnings Forecast for Lantern Pharma Inc. (NASDAQ:LTRN) Issued By Zacks Small Cap - Defense World

Aug 14, 2024

Aug 12, 2024

LTRN: Second Quarter Results - Yahoo Finance

Aug 12, 2024

Aug 11, 2024

The Targeted Pulse: The Practice-Changing Approval of Afami-cel for Advanced Synovial Sarcoma, Buprenorphine Offers Pain Relief for Bone Marrow Transplant, and More - Targeted Oncology

Aug 11, 2024

Aug 10, 2024

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript - Seeking Alpha

Aug 10, 2024

Aug 09, 2024

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

Aug 09, 2024

Aug 08, 2024

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 - MSN

Aug 08, 2024

Aug 08, 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan

Aug 08, 2024

Aug 07, 2024

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Business Wire

Aug 07, 2024

Aug 07, 2024

Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World

Aug 07, 2024

Aug 06, 2024

LTRN: Harmonic Clinical Update - Zacks Small Cap Research

Aug 06, 2024